Why the study?
FLT3 inhibitors improve outcomes in FLT3-mutated acute myeloid leukemia, but interpreting cardiovascular events is complicated by anthracycline exposure, hematopoietic stem cell transplantation, infection, electrolyte disturbances, and supportive-care medications.
What is the cardiovascular toxicity risk, and how should it be monitored and managed, in patients with FLT3-mutated acute myeloid leukemia treated with FLT3 inhibitors?
What is the cardiovascular toxicity risk, and how should it be monitored and managed, in patients with FLT3-mutated acute myeloid leukemia treated with FLT3 inhibitors?
This targeted narrative review highlights that QT prolongation is the best-established cardiovascular toxicity of FLT3 inhibitors in AML (especially quizartinib and gilteritinib) requiring label-directed ECG monitoring, whereas evidence for heart failure and myocardial/pericardial injury remains largely observational.
Answers are grounded in this paper and cite their sources.
Reinforces ECG monitoring for QT prolongation with quizartinib and gilteritinib in AML; leaves open prospective validation of other cardiotoxicity protocols.
FMS-like tyrosine kinase 3 (FLT3) inhibitors improve outcomes in FLT3-mutated acute myeloid leukemia (AML), but interpreting cardiovascular events is complicated by prior or concurrent anthracycline exposure, hematopoietic stem cell transplantation, infection, electrolyte disturbances, and multiple supportive-care medications. We conducted a targeted narrative review of PubMed/MEDLINE, ClinicalTrials.gov, current U.S. and European product information, professional guidance, and primary regulatory and clinical reports through 5 November 2026. For randomized comparisons with exact counts, we calculated unadjusted within-trial risk differences and risk ratios; heterogeneous data were neither pooled nor compared across agents. The strongest drug-specific evidence concerns QT prolongation and label-directed electrocardiographic monitoring, particularly for quizartinib and gilteritinib. Evidence for heart failure and myocardial or pericardial injury remains less certain and is largely observational or case-based. We organize monitoring and management by agent and treatment phase and distinguish label requirements from guideline-based or pragmatic recommendations. FLT3-specific approaches to imaging, biomarkers, treatment interruption, and rechallenge still require prospective study.
No takes yet. Share an insight, caveat, or question.
Khalid et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: